Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 EUR | 0.00% |
|
-2.08% | +22.40% |
04-29 | S.M.A.I.O S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-23 | S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.40% | 21.07M | - | ||
+51.99% | 798B | C+ | ||
-5.72% | 356B | C+ | ||
+18.94% | 328B | B- | ||
+11.07% | 304B | C+ | ||
+17.19% | 244B | B+ | ||
+2.94% | 227B | A+ | ||
+11.10% | 216B | B- | ||
+7.59% | 166B | C+ | ||
-3.65% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ALSMA Stock
- Ratings SMAIO